最 低 价：￥419.20
定 价：￥524.00
作 者：Frank A. Sloan，Chee-RueyHsieh 著 著
出 版 社：Oversea Publishing House
出版时间：2007-4-1
I S B N：9780521874908
| 作者简介：Frank Sloan has been the J. Alexander McMahon Professor of Health Policy and Management and Professor of Economics at Duke University since 1993, where he holds faculty appointments in the Department of Economics, the School of Public Policy, the Fuqua School of Business, and the School of Nursing. Before joining the faculty at Duke, he was a research economist at the Rand Corporation and served on the faculties of the University of Florida and Vanderbilt University. His current research interests include alcohol use and smoking prevention, long-term care, medical malpractice, and cost-effectiveness analyses of medical technologies. Professor Sloan also has a long-standing interest in hospitals, health care financing, and health manpower. He has served on several national advisory public and private groups, including the Physician Payment Review Commission. He has been a member of the Institute of Medicine of the National Academy of Sciences since 1982, recently chairing IOM committees on vaccine financing and cancer in low- and middle-income countries. He recently received a Merit Award from the National Institutes of Health and an Investigator Award from the Robert Wood Johnson Foundation. Professor Sloan's most recent books include The Smoking Puzzle: Information, Risk Perceptions, and Choice (2003) with Drs V. Kerry Smith and Donald H. Taylor, Jr., and The Price of Smoking with Drs Jan Ostermann, Gabriel Picone, Christopher Conover, and Donald H. Taylor, Jr. (2004). Professor Sloan received his Ph.D. in economics from Harvard University in 1969. |
| List of Tables List of Figures Contributors Acknowledgments 1. Introduction PART I. THE INDUSTRY STRUCTURE OF PHARMACEUTICAL INNOVATION 2. The Pharmaceutical Sector in Health Care 3. The Economics of Research and Development in the Pharmaceutical Industry PART 1I. STRUCTURING INCENTIVES FOR RESEARCH AND DEVELOPMENT 4. Drugs for Neglected Diseases: New Incentives for Innovation 5. When Patents Fail: Finding New Drugs for the Developing World 6. Implementing a Public Subsidy for Vaccines 7. Ensuring the Future Supply of Vaccines: Is a National Vaccine Authority the Answer? PART III. COMPETITION AND MARKETING 8. Competition between Generic and Branded Drugs 9. The United States' Experience with Direct-to-Consumer Advertising of Prescription Drugs: What Have We Learned? PART IV. PUBLIC EVALUATION OF THE BENEFITS AND COSTS OF INNOVATION 10. Measures of Costs and Benefits for Drugs in Cost-Effectiveness Analysis 11. Using Economic Evaluation in Reimbursement Decisions for Health Technologies: Lessons from International Experience 12. Pharmaceutical Spending and Health Outcomes 13. Pharmaceutical Innovation and Health Outcomes: Empirical Evidence from Taiwan 14. Conclusions and Policy Implications Notes References lndex |
内容加载中，请稍后...
商品评论（0条）